Week In Review: Fosun Signs $840 Million Deal For U.S. Rights To Henlius' PD-1

Shanghai Fosun Pharma announced it has licensed US rights to a PD-1 candidate from its longstanding partner Henlius Biotech in an $840 million agreement. Read more here...

Related Keywords

Kaitai ,Guizhou ,China ,Germany ,Shanghai ,Wuxi ,Jiangsu ,Lupeng ,Guangdong ,Philadelphia ,Pennsylvania ,United States ,Suzhou ,Fenghua ,Zhejiang ,Dundalk ,Louth ,Ireland ,Switzerland ,Hangzhou ,Nanjing ,Swiss ,Yifan Pharma ,Marinus Ztalmy ,Marinus Pharma ,Xiaochun Yu ,Fosun Pharma ,Zhuhai Biotheus ,Jiangsu Hansoh Pharma ,Simcere Pharma ,Company News ,Research Laboratory ,Temasek ,Innovative Technology ,Scientific Lab For Medicine ,Modern Medical Research Laboratory ,Two Scientists Wearing Face Masks ,Analyse Sample ,Petri Dish ,Discuss Innovative ,Advanced Scientific Lab ,Henlius Biotech ,Although Fosun ,Evive Biotechnology ,Acrotech Biotech ,Granulocyte Colony Stimulating Factor ,Hansoh Pharma ,Lupeng Pharmaceutical ,Kaitai Capital ,Series Pre A ,Chairman Xiaochun ,Lapam Capital ,Fenghua Venture ,Westlake Innovation Capital ,Long Yield Venture ,Wuxi Biologics ,Harbour Biomed ,Wuxi Vaccine ,Everest Medicines ,Greater China ,Nuance Pharma ,China Phase ,Southeast Asia ,Bavarian Nordic ,Bavarian Nordic Phase ,